Merck gets a leg-up for Keytruda in first-line kidney cancer

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the increasingly competitive first-line kidney cancer market. 

Merck, Eisai get triple approvals for Keytruda/Lenvima combi...

Raising the bar in liver cancer therapy

Eisai’s EMEA CEO Gary Hendler on why quality of life is key ...

Eisai angry over thyroid cancer drug impasse in England

Thyroid cancer drug falls through gap in NHS funding